Neuroprotective properties of calcium-channel blockers

M. H. Zornow, Donald Prough

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Increases in intraneuronal Ca2+ concentration, which accompany cerebral ischemia and traumatic brain injury, initiate a cascade of biochemical events that can eventually result in cell lysis and death. Calcium-channel blockers, in certain experimental models of focal and global ischemia, attenuate the increase in intracellular Ca2+ concentration and thereby ameliorate neurologic damage. Clinical efficacy varies among disease states. After nontraumatic subarachnoid hemorrhage, nimodipine has become a standard of care. Calcium-channel blockers improve outcome, whether given before or after onset of vasospasm. Although the precise mechanism of their beneficial effect remains unclear (vasodilation vs. attenuation of increases in intracellular Ca2+ concentrations), numerous studies have demonstrated decreased neurologic morbidity. Although there also is suggestive evidence of benefit in human stroke, these results have not been sufficiently impressive to result in the widespread use of these drugs as neuroprotectants. In clinical trials after cardiac arrest, calcium-channel blockers have been ineffective. In clinical traumatic brain injury, data suggest moderate efficacy in younger patients and those with post-traumatic subarachnoid hemorrhage, although overall outcome is not changed. The future role of calcium-channel blockers as neuroprotectants appears bright. Newer classes of compounds, with greater specificity and fewer side effects, may provide greater clinical benefit.

Original languageEnglish (US)
Pages (from-to)107-114
Number of pages8
JournalNew Horizons: Science and Practice of Acute Medicine
Volume4
Issue number1
StatePublished - 1996

Fingerprint

Calcium Channel Blockers
Neuroprotective Agents
Nervous System
Traumatic Subarachnoid Hemorrhage
Nimodipine
Subarachnoid Hemorrhage
Standard of Care
Heart Arrest
Brain Ischemia
Vasodilation
Cell Death
Theoretical Models
Ischemia
Stroke
Clinical Trials
Morbidity
Pharmaceutical Preparations
Traumatic Brain Injury

Keywords

  • brain
  • brain injury
  • calcium
  • calcium-channel blocker
  • central nervous system
  • cerebral blood flow

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Neuroprotective properties of calcium-channel blockers. / Zornow, M. H.; Prough, Donald.

In: New Horizons: Science and Practice of Acute Medicine, Vol. 4, No. 1, 1996, p. 107-114.

Research output: Contribution to journalArticle

@article{f835518ab87242a4b21aa0e2ac2908d8,
title = "Neuroprotective properties of calcium-channel blockers",
abstract = "Increases in intraneuronal Ca2+ concentration, which accompany cerebral ischemia and traumatic brain injury, initiate a cascade of biochemical events that can eventually result in cell lysis and death. Calcium-channel blockers, in certain experimental models of focal and global ischemia, attenuate the increase in intracellular Ca2+ concentration and thereby ameliorate neurologic damage. Clinical efficacy varies among disease states. After nontraumatic subarachnoid hemorrhage, nimodipine has become a standard of care. Calcium-channel blockers improve outcome, whether given before or after onset of vasospasm. Although the precise mechanism of their beneficial effect remains unclear (vasodilation vs. attenuation of increases in intracellular Ca2+ concentrations), numerous studies have demonstrated decreased neurologic morbidity. Although there also is suggestive evidence of benefit in human stroke, these results have not been sufficiently impressive to result in the widespread use of these drugs as neuroprotectants. In clinical trials after cardiac arrest, calcium-channel blockers have been ineffective. In clinical traumatic brain injury, data suggest moderate efficacy in younger patients and those with post-traumatic subarachnoid hemorrhage, although overall outcome is not changed. The future role of calcium-channel blockers as neuroprotectants appears bright. Newer classes of compounds, with greater specificity and fewer side effects, may provide greater clinical benefit.",
keywords = "brain, brain injury, calcium, calcium-channel blocker, central nervous system, cerebral blood flow",
author = "Zornow, {M. H.} and Donald Prough",
year = "1996",
language = "English (US)",
volume = "4",
pages = "107--114",
journal = "New horizons (Baltimore, Md.)",
issn = "1063-7389",
publisher = "Williams & Wilkins Co.",
number = "1",

}

TY - JOUR

T1 - Neuroprotective properties of calcium-channel blockers

AU - Zornow, M. H.

AU - Prough, Donald

PY - 1996

Y1 - 1996

N2 - Increases in intraneuronal Ca2+ concentration, which accompany cerebral ischemia and traumatic brain injury, initiate a cascade of biochemical events that can eventually result in cell lysis and death. Calcium-channel blockers, in certain experimental models of focal and global ischemia, attenuate the increase in intracellular Ca2+ concentration and thereby ameliorate neurologic damage. Clinical efficacy varies among disease states. After nontraumatic subarachnoid hemorrhage, nimodipine has become a standard of care. Calcium-channel blockers improve outcome, whether given before or after onset of vasospasm. Although the precise mechanism of their beneficial effect remains unclear (vasodilation vs. attenuation of increases in intracellular Ca2+ concentrations), numerous studies have demonstrated decreased neurologic morbidity. Although there also is suggestive evidence of benefit in human stroke, these results have not been sufficiently impressive to result in the widespread use of these drugs as neuroprotectants. In clinical trials after cardiac arrest, calcium-channel blockers have been ineffective. In clinical traumatic brain injury, data suggest moderate efficacy in younger patients and those with post-traumatic subarachnoid hemorrhage, although overall outcome is not changed. The future role of calcium-channel blockers as neuroprotectants appears bright. Newer classes of compounds, with greater specificity and fewer side effects, may provide greater clinical benefit.

AB - Increases in intraneuronal Ca2+ concentration, which accompany cerebral ischemia and traumatic brain injury, initiate a cascade of biochemical events that can eventually result in cell lysis and death. Calcium-channel blockers, in certain experimental models of focal and global ischemia, attenuate the increase in intracellular Ca2+ concentration and thereby ameliorate neurologic damage. Clinical efficacy varies among disease states. After nontraumatic subarachnoid hemorrhage, nimodipine has become a standard of care. Calcium-channel blockers improve outcome, whether given before or after onset of vasospasm. Although the precise mechanism of their beneficial effect remains unclear (vasodilation vs. attenuation of increases in intracellular Ca2+ concentrations), numerous studies have demonstrated decreased neurologic morbidity. Although there also is suggestive evidence of benefit in human stroke, these results have not been sufficiently impressive to result in the widespread use of these drugs as neuroprotectants. In clinical trials after cardiac arrest, calcium-channel blockers have been ineffective. In clinical traumatic brain injury, data suggest moderate efficacy in younger patients and those with post-traumatic subarachnoid hemorrhage, although overall outcome is not changed. The future role of calcium-channel blockers as neuroprotectants appears bright. Newer classes of compounds, with greater specificity and fewer side effects, may provide greater clinical benefit.

KW - brain

KW - brain injury

KW - calcium

KW - calcium-channel blocker

KW - central nervous system

KW - cerebral blood flow

UR - http://www.scopus.com/inward/record.url?scp=0029874576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029874576&partnerID=8YFLogxK

M3 - Article

C2 - 8689265

AN - SCOPUS:0029874576

VL - 4

SP - 107

EP - 114

JO - New horizons (Baltimore, Md.)

JF - New horizons (Baltimore, Md.)

SN - 1063-7389

IS - 1

ER -